Want to see LIVN full AI Analyst Report?
LIVN Stock Chart & Stats
$78.19
$2.39(3.06%)
At close: 4:00 PM EDT
$78.19
$2.39(3.06%)
Day’s Range― - ―
52-Week Range$48.57 - $85.76
Previous Close$80.58
Volume486.52K
Average Volume (3M)679.02K
Market Cap
$4.40B
Enterprise Value$4.46K
Total Cash (Recent Filing)$516.62M
Total Debt (Recent Filing)$351.95M
Price to Earnings (P/E)40.7
Beta1.03
Next Earnings
Nov 04, 2026EPS Estimate
1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.45
Shares Outstanding54,933,537
10 Day Avg. Volume569,513
30 Day Avg. Volume679,019
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.79
Price to Sales (P/S)2.42
P/FCF Ratio19.36
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$88.83Price Target Upside13.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)4.25
Revenue Forecast (FY)$1.51B
Bulls Say, Bears Say
Bulls Say
Revenue & Margin ReboundConsistent top-line growth with materially higher gross and operating margins indicates durable unit economics. High gross margins (~71%) from implantable devices plus consumable pull-through support operating leverage and sustained profitability, strengthening long-term earnings power.
Cardiopulmonary Momentum & SupplyA secured supply agreement and added production capacity reduce component risk and enable oxygenator scale-up. The Essenz upgrade cycle driving a higher share of HLM placements creates recurring consumable pull-through and structural market-share gains in cardiopulmonary, supporting durable revenue streams.
Improving Balance Sheet & LiquidityMeaningful debt paydown and a sizeable cash balance improve leverage and liquidity. Stronger balance-sheet flexibility reduces refinancing risk and provides capacity to fund capex, R&D and strategic initiatives over the medium term while supporting resilient capital allocation.
Bears Say
Higher CapEx & Lower FCF GuidanceManagement is investing to scale cardiopulmonary capacity and supply, but higher near-term capex compresses free cash flow. Reduced FCF guidance reflects durable investment needs that will limit near-term cash conversion and constrain discretionary capital for buybacks or dividends in the coming months.
Earnings And Cash-Conversion VolatilityThe company has swung from a 2025 net loss to TTM profitability, but cash conversion lags earnings. This historical volatility in earnings and FCF undermines predictability, raising execution risk for converting revenue and margin gains into stable, repeatable free cash flow.
Regulatory Timing Risk For OSAA delayed PMA supplement for the MRI‑compatible OSA system pushes the commercial timeline. Regulatory timing slips can meaningfully postpone expected OSA revenue and defer realization of medium‑term product targets, slowing the path to the company’s 2030 OSA revenue ambitions.
LivaNova News
LIVN FAQ
What was LivaNova PLC’s price range in the past 12 months?
LivaNova PLC lowest stock price was $48.57 and its highest was $85.76 in the past 12 months.
What is LivaNova PLC’s market cap?
LivaNova PLC’s market cap is $4.40B.
When is LivaNova PLC’s upcoming earnings report date?
LivaNova PLC’s upcoming earnings report date is Nov 04, 2026 which is in 87 days.
How were LivaNova PLC’s earnings last quarter?
LivaNova PLC released its earnings results on Aug 05, 2026. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.094 by $0.166.
Is LivaNova PLC overvalued?
According to Wall Street analysts LivaNova PLC’s price is currently Undervalued.
Does LivaNova PLC pay dividends?
LivaNova PLC does not currently pay dividends.
What is LivaNova PLC’s EPS estimate?
LivaNova PLC’s EPS estimate is 1.06.
How many shares outstanding does LivaNova PLC have?
LivaNova PLC has 54,933,537 shares outstanding.
What happened to LivaNova PLC’s price movement after its last earnings report?
LivaNova PLC reported an EPS of $1.26 in its last earnings report, beating expectations of $1.094. Following the earnings report the stock price went down -8.415%.
Which hedge fund is a major shareholder of LivaNova PLC?
Currently, no hedge funds are holding shares in LIVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LivaNova Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$88.83 (13.61% Upside)
$88.83 (13.61% Upside)
Blogger Sentiment
Bullish
LIVN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 874.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $232.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 15.2%
Last 30 Days ▲ 15.2%
News Sentiment
Very Bullish
Bullish news 86%
Bearish news 14%
Bearish news 14%
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.61%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.35%
Trailing 12-Months
Company Description
LivaNova PLC
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
LIVN Company Deck
LIVN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial story: record revenue and EPS, raised top-line and EPS guidance, strong growth and market-share gains in Cardiopulmonary and Epilepsy, strategic supply and manufacturing actions (Thermo Fisher agreement, new production line), and compelling clinical data supporting future adoption. Offsetting items are largely strategic investments (higher CapEx, R&D, IT), a one-time tariff refund that boosted margins and EPS in the quarter but will not recur, modest delays in OSA regulatory timing, and a lowered near-term free cash flow outlook. On balance the positive execution, guidance increases and durable innovation pipeline outweigh the near-term cash and one-time headwind items.View all LIVN earnings summariesLIVN Stock 12 Month Forecast
Average Price Target
$88.83
▲(13.61% Upside)
Technical Analysis
Artivion
―
Integer Holdings
―
Ufp Technologies
―
Inspire Medical Systems
―
TransMedics Group
―
Ownership Overview
0.40% Insiders
37.02% Mutual Funds
8.87% Other Institutional Investors
28.76% Public Companies and
Individual Investors